Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 192 results for "Emixustat Hydrochloride"

Emixustat hydrochloride (formerly known as ACU-4429) Macular E...

Research and Markets ( has announced the addition of the "Emixustat (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering. Currently the ..., 1 month ago

1 images for "Emixustat Hydrochloride"

Securities Technology Monitor, 6 months ago

Washington State Court Issues Order Requiring Acucela to Hold Special Shareholders Meeting

SEATTLE--(BUSINESS WIRE)-- Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic ...
 CNBC1 month ago Acucela Files Opposition to SBI/Kubota Motion to Compel Company to Call Special Shareholders Meeting  CEOWorld Magazine1 month ago Acucela to Hold 2015 Annual Meeting of Shareholders on June 8, 2015  CEOWorld Magazine1 month ago

Diabetic Macular Edema Therapeutics Pipeline Market H1 2015 Review Report Available at

PRWeb The report "Diabetic Macular Edema - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Diabetic Macular Edema. Diabetic macular edema is swelling of the retina in diabetes mellitus due to ...
 Crawford Financial Planning1 month ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Emixustat Hydrochloride
Get updated on latest news & your favorite topics right in your inbox!
More     Less